Topotecan Injection, Concentrate
Generic name: topotecan hydrochloride
Dosage form: injection, solution, concentrate
Drug class:Miscellaneous antineoplastics
Medically reviewed by Drugs.com. Last updated on May 23, 2022.
On This Page
- Boxed Warning
- Indications and Usage
- Dosage and Administration
- Dosage Forms and Strengths
- Contraindications
- Warnings and Precautions
- Adverse Reactions/Side Effects
- Use In Specific Populations
- Overdosage
- Description
- Clinical Pharmacology
- Nonclinical Toxicology
- Clinical Studies
- References
- How Supplied/Storage and Handling
- Patient Counseling Information
Topotecan can cause severe myelosuppression. Administer first cycle only to patients with baseline neutrophil counts of greater than or equal to 1,500/mm3 and platelet counts greater than or equal to 100,000/mm3. Monitor blood cell counts [see Warnings and Precautions (5.1)].
Indications and Usage for Topotecan Injection, Concentrate
Ovarian Cancer
Topotecan Injection, as a single agent, is indicated for the treatment of patients with metastatic ovarian cancer after disease progression on or after initial or subsequent chemotherapy.
Small Cell Lung Cancer
Topotecan Injection, as a single agent, is indicated for the treatment of patients with small cell lung cancer (SCLC) with platinum-sensitive disease who progressed at least 60 days after initiation of first-line chemotherapy.
Cervical Cancer
Topotecan Injection, in combination with cisplatin, is indicated for the treatment of patients with Stage IV-B, recurrent, or persistent cervical cancer not amenable to curative treatment.
Topotecan Injection, Concentrate Dosage and Administration
Important Safety Information
Calculate dosage using body surface area. Do not exceed a single dose of 4 mg intravenously.
...